Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI-based HAIC Combined With Fruquintinib for Colorectal Cancer Liver Metastases
NCT07024537Phase 2Completed
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in Colorectal cancer with liver metastases (CRLM). Started Jan 2023; status: completed.
02
Drugs
fruquintinib
03
Conditions
Colorectal cancer with liver metastases (CRLM)
Beyond the preview
Go deeper on NCT07024537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024537.